Published :
Tables : 47
Figures : 43
Category : Healthcare
No. of Pages : 226
Report Code : HC-U4750
Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is poised to register a CAGR of 5.1% during the forecast period 2022 to 2028. The first immunisation given to infants is often the DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccine at two months of age. The capital "D" and "P" in DTaP refer to the higher amounts of Diphtheria and Pertussis antigens compared to Tdap products. Three contagious human diseases—diphtheria, tetanus, and pertussis—are prevented by the diphtheria, pertussis, and tetanus (DPT) vaccination. To generate acquired immunity against Diphtheria, Pertussis, and Tetanus, these vaccines are administered either during childhood or during middle life. DTP, also known as diphtheria, tetanus, and pertussis, are severe illnesses brought on by the bacteria. Diphtheria, tetanus, and pertussis vaccines are combined and administered intramuscularly as the DTP vaccine. In order to successfully immunise children up to the age of seven against Diphtheria, Tetanus, and Pertussis (whooping cough), diphtheria and tetanus toxoids and the pertussis vaccine are advised concurrently. This trend has primarily been caused by an increase in demand for combination vaccinations that are tetravalent and then pentavalent. The funding provided by GAVI (Global Alliance for Vaccines and Immunizations) for further DTP-containing vaccines has played a significant role in driving the rising demand for combination products. The pertussis vaccine market is expected to increase rapidly due to the high birth rate and rising demand for the vaccine, which will favourably affect the worldwide Diphtheria, Pertussis and Tetanus (DTP) Vaccine market. Other factors anticipated to contribute to market expansion include a rise in the frequency of DPT cases, improvements in vaccine administration systems, the creation of technologically sophisticated vaccines, and government initiatives FutureWise Market Research has instantiated a report that provides an intricate analysis of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market: • AJ Vaccines • Bionet-Asia • GlaxoSmithKline plc (GSK) • Johnson & Johnson • Massbiologics • Meiji Holdings Co., Ltd. (KM biologics Co., Ltd.) • Merck & Co., Inc • Panacea Biotec Ltd. • Sanofi • Serum Institute of India Pvt. Ltd. (Note: The list of the major players will be updated with the latest market scenario and trends) Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Segmentation: By Product Type • DTaP Vaccine • TD Vaccine • Tdap Vaccine By Age Group • Adult • Pediatrics By End User • Hospitals • Clinics • Vaccination Centers By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Sample Video: Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market By Product Type, By Age Group, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The first immunisation given to infants is often the DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccine at two months of age. The capital "D" and "P" in DTaP refer to the higher amounts of Diphtheria and Pertussis antigens compared to Tdap products. Three contagious human diseases—diphtheria, tetanus, and pertussis—are prevented by the diphtheria, pertussis, and tetanus (DPT) vaccination. To generate acquired immunity against Diphtheria, Pertussis, and Tetanus, these vaccines are administered either during childhood or during middle life. DTP, also known as diphtheria, tetanus, and pertussis, are severe illnesses brought on by the bacteria. Diphtheria, tetanus, and pertussis vaccines are combined and administered intramuscularly as the DTP vaccine. In order to successfully immunise children up to the age of seven against Diphtheria, Tetanus, and Pertussis (whooping cough), diphtheria and tetanus toxoids and the pertussis vaccine are advised concurrently. This trend has primarily been caused by an increase in demand for combination vaccinations that are tetravalent and then pentavalent. The funding provided by GAVI (Global Alliance for Vaccines and Immunizations) for further DTP-containing vaccines has played a significant role in driving the rising demand for combination products. The pertussis vaccine market is expected to increase rapidly due to the high birth rate and rising demand for the vaccine, which will favourably affect the worldwide Diphtheria, Pertussis and Tetanus (DTP) Vaccine market. Other factors anticipated to contribute to market expansion include a rise in the frequency of DPT cases, improvements in vaccine administration systems, the creation of technologically sophisticated vaccines, and government initiatives
FutureWise Market Research has instantiated a report that provides an intricate analysis of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market: • AJ Vaccines • Bionet-Asia • GlaxoSmithKline plc (GSK) • Johnson & Johnson • Massbiologics • Meiji Holdings Co., Ltd. (KM biologics Co., Ltd.) • Merck & Co., Inc • Panacea Biotec Ltd. • Sanofi • Serum Institute of India Pvt. Ltd. (Note: The list of the major players will be updated with the latest market scenario and trends)
Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Segmentation: By Product Type • DTaP Vaccine • TD Vaccine • Tdap Vaccine
By Age Group • Adult • Pediatrics
By End User • Hospitals • Clinics • Vaccination Centers
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Sample Video:
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market By Product Type, By Age Group, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. DTaP Vaccines 7.2. TD Vaccines 7.3. Tdap Vaccines 8. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Age Group Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Adult 8.2. Pediatric 9. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals 9.2. Clinics 9.3. Vaccination Centers 10. North America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. AJ Vaccines 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Bionet-Asia 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. GlaxoSmithKline plc (GSK) 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Johnson & Johnson 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Massbiologics 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Meiji Holdings Co., Ltd. (KM biologics co., Ltd.) 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Merck & Co., Inc. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Panacea Biotec Ltd. 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Sanofi 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Serum Institute of India Pvt. Ltd. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. DTaP Vaccines 7.2. TD Vaccines 7.3. Tdap Vaccines
8. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By Age Group Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Adult 8.2. Pediatric
9. Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals 9.2. Clinics 9.3. Vaccination Centers
10. North America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. AJ Vaccines 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Bionet-Asia 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. GlaxoSmithKline plc (GSK) 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Johnson & Johnson 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Massbiologics 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Meiji Holdings Co., Ltd. (KM biologics co., Ltd.) 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Merck & Co., Inc. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Panacea Biotec Ltd. 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Sanofi 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Serum Institute of India Pvt. Ltd. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics